



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	4.04
Trade Time:	4:02 PM ET 05/26/17
Change:	0.09 <span style="color: green;">▲</span> (2.278%)
Day Range	3.91 - 4.06
52-Week Range	1.27 - 7.10
Volume	272,186

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [05/08/17  
Rexahn Pharmaceuticals to Present RX-3117  
Clinical Data at the American Society of  
Clinical Oncology \(ASCO\) 2017 Annual  
Meeting](#)
- [05/05/17  
Rexahn Effects 1-for-10 Reverse Stock Split](#)
- [05/04/17  
Rexahn Pharmaceuticals Reports First  
Quarter 2017 Financial Results and Provides  
Corporate Update](#)
- [04/13/17  
Rexahn Announces 1-for-10 Reverse Stock  
Split](#)
- [02/27/17  
Rexahn Pharmaceuticals Reports Full Year  
2016 Financial Results and Provides  
Corporate Update](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- [02/24/17  
Annual Report \(10-K\)](#)
- [02/24/17  
Proxy Statement \(DEF 14A\)](#)
- [05/03/17  
Quarterly Report \(10-Q\)](#)
- [11/04/16  
Quarterly Report \(10-Q\)](#)
- [08/05/16  
Quarterly Report \(10-Q\)](#)